A large study by researchers at Stanford Medicine has found that the risk of secondary blood cancers after CAR-T cell therapy -; a cell-based cancer treatment that exploded on the scene in 2017 as a treatment for intractable blood cancers -; is low, despite a Food and Drug Administration warning.
RapidClaims Emerges from Stealth with $3.1M to Tackle Healthcare Claim Denials with AI
Dushyant Mishra (CEO), Jot Sarup Sahni (CPTO), and Abhinay Vyas (CDO) What You Should Know: – RapidClaims, a healthcare technology startup focused on automating medical
February 16, 2024